BDSX: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Revenues	59,744	-
Direct costs and expenses (less employee related expenses and depreciation and amortization)	8,634	-
Employee related expenses (less share-based compensation expenses)	48,703	-
Contracted services expenses	5,691	-
Sales and marketing education and event expenses	5,601	-
Occupancy and equipment service expenses	3,079	-
Clinical trials and associated costs	1,287	-
Depreciation and amortization expense	4,283	-
Share-based compensation expenses	3,064	-
Interest expense	5,657	-
Change in fair value of warrant liability, net	280	-
Other segment items	4,750	-
Net loss	-31,285	-22,569
Depreciation and amortization	4,283	2,876
Accretion of lease right-of-use assets	-88	-59
Share-based compensation expense	3,064	2,011
Change in fair value of warrant liability, net	280	280
Provision for credit losses	109	109
Accrued interest, amortization of debt issuance costs and other	971	639
Inventory excess and obsolescence	21	11
Impairment loss on intangible assets	106	99
Accounts receivable	4,139	-1,085
Other current assets	-334	-318
Other long-term assets	130	5
Accounts payable and other accrued liabilities	885	399
Deferred revenue	2,014	-114
Current and long-term operating lease liabilities	-474	-250
Net cash, cash equivalents, and restricted cash used in operating activities	-24,049	-15,170
Purchase of property and equipment	173	125
Patent costs and intangible asset acquisition, net	126	107
Net cash, cash equivalents, and restricted cash used in investing activities	-299	-232
Proceeds from the issuance of common stock	5,000	-
Proceeds from issuance of common stock under employee stock purchase plan	497	313
Proceeds from term loan and notes payable	10,000	10,000
Repayment of term loan and notes payable	16	12
Payment of debt issuance costs	30	27
Equity financing costs	188	-
Other	-555	-388
Net cash, cash equivalents, and restricted cash provided by financing activities	14,708	9,886
Net (decrease) increase in cash, cash equivalents, and restricted cash	-9,640	-5,516
Cash and cash equivalents at beginning of period	26,332	-
Cash and cash equivalents at end of period	16,692	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

BDSX: the cashflow